Evidence map›Paper›PMID 29079642›Full record

ArticleThe Journal of biological chemistry2017

Third time lucky? Getting a grip on matrix metalloproteinases.

F Xavier Gomis-Rüth

Abstract readComment
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Tetracyclines-An Important Therapeutic Tool for Dermatologists.International journal of environmental research and public health · 2022
    Review
  2. Article
  3. Review
  4. Proteases: Pivot Points in Functional Proteomics.Methods in molecular biology (Clifton, N.J.) · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

F Xavier Gomis-RüthFrom the Proteolysis Laboratory, Molecular Biology Institute of Barcelona (Consejo Superior de Investigaciones Científicas), Barcelona Science Park, Baldiri Reixac 15-21, 08028 Barcelona, Catalonia, Spain xgrcri@ibmb.csic.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug candidates against matrix metalloproteinases (MMPs) failed in the clinic in the past because their strong zinc-targeting warheads led to a lack of specificity. More recently, significant selectivity among MMPs was achieved by blocking the enzymes' specificity pockets, nearby exosites, and downstream domains. Scannevin and colleagues now elegantly twist the plot and achieve ultimate selectivity: They target MMP-9 by allosterically preventing activation of its zymogen.

Indexed as

Matrix Metalloproteinase 9Matrix MetalloproteinasesEnzyme PrecursorsEnzyme PrecursorsMatrix Metalloproteinase 9Matrix Metalloproteinases

Identifiers

PMID29079642
PMCPMC5663894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.